Los mejores oncólogos pediátricos — TOP-379 médicos

• Se especializa en Oncología Pediátrica, tratando cánceres como leucemia, linfoma, tumores cerebrales.
• No hay información sobre práctica o capacitación internacional específica disponible para oncología pediátrica.
• No se mencionan estadísticas ni tasas de éxito específicas de oncología pediátrica.
• No se proporciona una clasificación específica en Oncología Pediátrica.
• Posee certificaciones en múltiples campos médicos, mejorando la atención de Oncología Pediátrica.
• Membresías profesionales no especificadas para Oncología Pediátrica.
• Ofrece consultas online de Oncología Pediátrica, garantizando la accesibilidad del paciente.

El Dr. Girish V. Badarkhe es un oncólogo hematológico experimentado en el Centro de Cáncer HCG Manavata, Nashik, con títulos MBBS, MD y DM. Tiene más de 13 años de experiencia en leucemia, mieloma múltiple y trasplante de médula ósea, y ha recibido premios por su arduo trabajo profesional.

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

Sema Yılmaz was born on July 30, 1965. She received her undergraduate degree from Istanbul University Cerrahpaşa Medical Faculty and completed her medical residency training at the Department of Pediatrics at Zeynep Kamil Women's and Children's Health and Diseases Hospital. She also completed her medical subspecialty training in Pediatric Hematology/Oncology at Cukurova University. Her medical residency thesis was titled "The Relationship Between Morning First Urine Density and Nocturnal Enuresis in Children Aged 3-6 Years", and her medical subspecialty thesis was titled "Comparison of Sphingosine 1-phosphate Receptor 4 Gene Expression in Healthy Children and Neuroblastoma Patients". She started her medical career as a general practitioner. After working as a general practitioner for 4 years, she worked as a doctor researcher at Zeynep Kamil Women's and Children's Health and Diseases Training and Research Hospital for 5 years. She then served as a specialist doctor, assistant professor, and associate professor at various institutions. She worked at Houston MD Anderson, North Carolina-UNC, Boston-Harvard University in the USA. Additionally, she conducted research on cell therapies. She received the title of professor in Pediatric Hematology/Oncology at Usak Medical Faculty. She is a member of the Turkish Pediatric Oncology Group, European Association for Cancer Research (EACR), Turkish Medical Association, Turkish National Pediatrics Association, Turkish Pediatrics Association, Pediatrics Specialty Academy Association (PUADER), Turkish Immunology Association, Turkish Hematology Association, and Molecular Oncology Association (MOKAD). She currently serves her patients at Koru Hospital. Her medical interests include:

Cell therapies in childhood cancers

Cancer immunology

Investigation of genetic pathways responsible for cancer and metastasis

Pulmonary microbiota

BAL transplantation